We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$42M
Cap. Flow %
-1.57%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Miscellaneous 90.18%
2 Healthcare 9.66%
3 Technology 0.11%
4 Consumer Staples 0.04%
5 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNTA
351
PUT
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-159
Closed -$172K
PGNX
352
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-361
Closed -$152K
PGNX
353
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-174,900
Closed -$738K
PGNX
354
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-130
Closed -$55K
DERM
355
DELISTED
Dermira, Inc.
DERM
– –
-26,693
Closed -$860K
ADYX
356
CALL
DELISTED
Adynxx Inc
ADYX
– –
-8
Closed -$54K
IPCI
357
PUT
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-12
Closed -$19K
VXZ
358
CALL
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
– –
-993
Closed -$5.49M
NVIV
359
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
-31
Closed -$3.87M
CEMP
360
DELISTED
Cempra, Inc.
CEMP
– –
-64,065
Closed -$1.38M
TEAR
361
DELISTED
TearLab Corporation
TEAR
– –
-188,235
Closed -$1.21M
CYNA
362
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
– –
-18,194
Closed -$305K
RLYP
363
CALL
DELISTED
RELYPSA INC COM
RLYP
– –
-115
Closed -$213K
RLYP
364
PUT
DELISTED
RELYPSA INC COM
RLYP
– –
-88
Closed -$163K
HTWR
365
PUT
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-89
Closed -$514K
CPXX
366
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-26,500
Closed -$800K
CBMX
367
DELISTED
CombiMatrix Corporation
CBMX
– –
-14,391
Closed -$41K
AST
368
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
– –
-308,909
Closed -$999K
ARLZ
369
CALL
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
– –
-413
Closed -$136K
ARLZ
370
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
– –
-228,364
Closed -$754K
NWBO
371
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
– –
-881,585
Closed -$512K
NWBO
372
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
– –
-813
Closed -$47K
MDVN
373
DELISTED
MEDIVATION, INC.
MDVN
– –
-4,500
Closed -$271K
MDVN
374
PUT
DELISTED
MEDIVATION, INC.
MDVN
– –
-45
Closed -$271K
VXX
375
CALL
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
– –
-19
Closed -$414K
11 12 13 14
15

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management's Q3 2016 filing shows 93 new, 88 increased, 106 reduced and 73 closed positions. Its largest new stake was Bristol-Myers Squibb: 156,887 shares worth $8.46M. The largest sale was Sarepta Therapeutics, an estimated $7.47M.

By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, up from 86% a quarter earlier, followed by Healthcare and Technology.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.